This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michels, K. B. Articles by Manson, J. E. Search for Related Content PubMed PubMed Citation Articles by Michels, K. B. Articles by Manson, J. E. Related Collections Epidemiology

(Circulation. 2003;107:1830.)
© 2003 American Heart Association, Inc.

Editorial

Postmenopausal Hormone Therapy

A Reversal of Fortune

Karin B. Michels, ScD, MSc; JoAnn E. Manson, MD, DrPH

From the Obstetrics & Gynecology Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology (K.B.M.), and the Division of Preventive Medicine, Department of Medicine (J.E.M.), Brigham and Women’s Hospital and Harvard Medical School; and the Department of Epidemiology, Harvard School of Public Health (K.B.M., J.E.M.), Boston, Mass.

Correspondence to Dr Karin B. Michels, Obstetrics & Gynecology Epidemiology Center, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail kmichels@rics.bwh.harvard.edu

Key Words: hormone replacement therapy, postmenopausal • epidemiology • trials, clinical • cardiovascular disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

How did it become common clinical practice in past decades to prescribe postmenopausal hormones for the prevention of coronary heart disease (CHD)? Postmenopausal hormone therapy (HT), although approved by the US Food and Drug Administration for the treatment of postmenopausal symptoms and the prevention of osteoporosis, was never approved for the prevention of CHD. The recent data from the Women’s Health Initiative (WHI) and other randomized clinical trials (RCTs) indicate that combined estrogen and progestin may increase, rather than decrease, CHD risk.¹ This news has alarmed women worldwide and has left physicians uncertain what to recommend to their patients. Recently, the North American Menopause Society released recommendations stating that estrogen and progestin should not be prescribed for primary or secondary prevention of CHD.² The effect of unopposed estrogen and other formulations of HT on CHD remains unclear; more insight on the former will emerge from the still-ongoing estrogen component of the WHI.

The surging popularity of HT use during the past few decades was largely based on findings from observational epidemiologic studies.^3,4 Observational studies suggested that HT may reduce the incidence of CHD, fractures, and colorectal cancer but may increase the incidence of endometrial cancer, breast cancer, stroke, and venous thromboembolism.^4,5 Notably, except for the divergent findings about CHD, the WHI findings were largely concordant with the observational studies (Figure). The relative risks for hip fractures and colorectal cancer with HT were reduced, whereas those for breast cancer, venous thromboembolism, and stroke were increased. At surprising odds . . . [Full Text of this Article]

This article has been cited by other articles:

				M.-N. Vercambre, A. Fournier, M.-C. Boutron-Ruault, F. Clavel-Chapelon, V. Ringa, and C. Berr Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies? Am. J. Epidemiol., December 15, 2007; 166(12): 1451 - 1460. [Abstract] [Full Text] [PDF]

				J. E. Manson and S. S. Bassuk Invited Commentary: Hormone Therapy and Risk of Coronary Heart Disease Why Renew the Focus on the Early Years of Menopause? Am. J. Epidemiol., September 1, 2007; 166(5): 511 - 517. [Abstract] [Full Text] [PDF]

				K. B Michels The women's health initiative--curse or blessing? Int. J. Epidemiol., August 1, 2006; 35(4): 814 - 816. [Full Text] [PDF]

				H. Caspard, A. K Chan, and A. M Walker Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment Ann. Pharmacother., January 1, 2006; 40(1): 21 - 26. [Abstract] [Full Text] [PDF]

				R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]

				P.W Serruys and J Aoki Therapeutic options for patients with chronic myocardial ischaemia Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E2 - E11. [Abstract] [Full Text]

				K. McPherson and E. Hemminki Synthesising licensing data to assess drug safety BMJ, February 28, 2004; 328(7438): 518 - 520. [Full Text] [PDF]

				K. McPherson Where are we now with hormone replacement therapy? BMJ, February 14, 2004; 328(7436): 357 - 358. [Full Text] [PDF]

				C. E.D. Chilvers, R. C. Knibb, S. J. Armstrong, K. L. Woods, and R. F.A. Logan Post menopausal hormone replacement therapy and risk of acute myocardial infarction -- a case control study of women in the East Midlands, UK Eur. Heart J., December 2, 2003; 24(24): 2197 - 2205. [Abstract] [Full Text] [PDF]

				E. Barrett-Connor An Epidemiologist Looks at Hormones and Heart Disease in Women J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042. [Full Text] [PDF]